Using intravascular ultrasound, researchers have found that intensive cholesterol lowering with a statin drug can regress the buildup of plaque in the coronary arteries, according to a study presented at the annual meeting of the American College of Cardiology in Atlanta.
Using intravascular ultrasound, researchers have found that intensive cholesterol lowering with a statin drug can regress the buildup of plaque in the coronary arteries, according to a study presented at the annual meeting of the American College of Cardiology in Atlanta.
Lead author Dr. Steven Nissen, a cardiologist at the Cleveland Clinic, said that previous similar studies had shown slowing of coronary disease but not regression. But Johns Hopkins University researchers in 2004 documented plaque regression in patients on statins using transesophageal MR imaging (Circulation 2004;110[16]:2336-2341).
The specific statin regimen in the Cleveland Clinic study significantly lowered bad cholesterol and markedly increased good cholesterol levels, according to Nissen. The mean baseline LDL cholesterol of 130.4 mg/dL dropped to 60.8 mg/dL in the study patients, a reduction of 53.2%. This is the largest reduction in cholesterol ever observed in a major statin outcome trial.
The mean HDL cholesterol (43.1 mg/dL at baseline) increased to 49.0 mg/dL, a 14.7% increase, which was also unprecedented. The arterial plaque overall was reduced by 6.8% to 9.1% for the various measures of disease burden.
This study was known by the acronym ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden Trial).
The trial was conducted at 53 community and tertiary-care centers in the U.S., Canada, Europe, and Australia. A total of 507 patients had baseline IVUS exams and received 40 mg daily of rosuvastatin (Crestor).
Atherosclerosis progression was assessed at baseline and after at 24 months of treatment.
For more information from the Diagnostic Imaging archives:
Optical coherence tomography characterizes arterial plaque
Coronary artery calcium score predicts future cardiac events
CT leads imaging field in plaque assessment
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.